Medicom Oncology Clinical Pearls Podcasts
ELOQUENT-2 updates represent the longest median FU of an immuno-oncology agent in MM
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:01:43
- Mas informaciones
Informações:
Sinopsis
Dr. Sagar Lonial provides a brief update on the ELOQUENT-2 phase 3 trial and how it continues to demonstrate a benefit in terms of progression-free survival.
